A phase 1/2 study of REGN7075 (EGFRA-CD28) combined with cemiplimab (anti-PD-1) In NSCLC: Trial in progress update Meeting Abstract
| Authors: | Johnson, M. L.; Girda, E.; Sohal, D.; Lakhani, N. J.; Olszanski, A. J.; Fong, L.; Kinnaman, M.; Han, H.; Moesta, A.; Hao, Y.; Li, S.; Ganguly, S.; Seebach, F.; Mathias, M.; Segal, N. H. |
| Abstract Title: | A phase 1/2 study of REGN7075 (EGFRA-CD28) combined with cemiplimab (anti-PD-1) In NSCLC: Trial in progress update |
| Meeting Title: | 2024 World Conference on Lung Cancer |
| Keywords: | nsclc; cemiplimab; regn7075 |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 19 |
| Issue: | 10 Suppl. |
| Meeting Dates: | 2024 Sep 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-10-01 |
| Start Page: | S391 |
| Language: | English |
| ACCESSION: | WOS:001337925602211 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2024.09.706 |
| Notes: | Meeting Abstract: P4.11D.04 -- Source: Wos |
